Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 799-806

  Kim, Yeon Jeong ^a   Hwang, Jae Seok ^b,c   Hong, Young Bin ^a,c   Bae, Insoo ^a,c   Seong, Yeon Sun ^a  

^a Dankook University   (South Korea)

^b Keimyung University   (South Korea)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

AsPC1 cells; Gemcitabine; MiaPaCa2; Pancreatic cancer; Protein kinase inhibitor; SB525334; Transforming growth factor receptor (T R)

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; GEMCITABINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; SB 525334; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; IMIDAZOLES; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; QUINOXALINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 84863352778     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin oncol 29: 9-16, 2002.
3. Kang SP and Saif MW: Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. J Pancreas 9: 251-266, 2008. (Pubitemid 351864885)
4. Itamochi H, Kigawa J and Terakawa N: Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99: 653-658, 2008. (Pubitemid 351448066)
5. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
6. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
7. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007. (Pubitemid 46972777)
8. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res 10: 2307-2318, 2004. (Pubitemid 38445688)
9. Giroux V, Iovanna J and Dagorn JC: Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 20: 1982-1991, 2006. (Pubitemid 44953898)
10. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577-584, 2003. (Pubitemid 37280136)
11. Bierie B and Moses HL: Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520, 2006. (Pubitemid 43980540)
12. Ikushima H and Miyazono K: TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424, 2010.
13. Moustakas A and Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520, 2007. (Pubitemid 47308444)
14. Oft M, Akhurst RJ and Balmain A: Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 4: 487-494, 2002. (Pubitemid 34752433)
15. Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G and Ten Dijke P: Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differenti-ally affecting tumor angiogenesis. Oncogene 29: 1351-1361, 2010.
16. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI and Korc M: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856, 1993. (Pubitemid 24002804)
17. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S and Korc M: Soluble type II transforming growth factor β (TGFβ) receptor inhibits TGFβ signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 7: 2931-2940, 2001. (Pubitemid 32911404)
18. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL and Chiao PJ: LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7: 829-840, 2008. (Pubitemid 351551036)
19. Sempere LF, Gunn JR and Korc M: A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Cancer Biol Ther 12: 198-207, 2011.
20. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI and Walker CL: Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 13: 3087-3099, 2007. (Pubitemid 46849586)
21. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
22. Ng SSW, Tsao MS, Chow S and Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60: 5451-5455, 2000.
23. Levy L and Hill CS: Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58, 2006. (Pubitemid 43117515)
24. Chow JY, Ban M, Wu HL, Nguyen F, Huang M, Chung H, Dong H and Carethers JM: TGFβ downregulates PTEN via activation of NFKB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 298: G275-282, 2010.
25. Chow JY, Quach KT, Cabrera BL, Cabrai JA, Beck SE and Carethers JM: RAS/ERK modulates TGFβ-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28: 2321-2327, 2007. (Pubitemid 350111590)
26. Wendt MK, Tian M and Schiemann WP: Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res 347: 85-101, 2012.
27. Novak A, Hsu SC, Leung-Hagesteijn C, Radeva G, Papkoff J, Montesano R, Roskelley C, Grosschedl R and Dedhar S: Cell adhesion and the integrin-linked kinase regulate the LEF-1 and β-catenin signaling pathways. Proc Natl Acad Sci USA 95: 4374-4379, 1998.
28. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P and Foidart JM: Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Res 63: 2658-2664, 2003. (Pubitemid 36605210)
29. Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45: 872-877, 2005. (Pubitemid 41060226)
30. Zhou J, Wang CY, Liu T, Wu B, Zhou F, Xiong JX, Wu HS, Tao J, Zhao G, Yang M and Gou SM: Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14: 925-930, 2008. (Pubitemid 351325033)
31. Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ and Xu XX: A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56: 371-378, 2009.
32. Yao J, Cai HH, Wei JS, An Y, Ji ZL, Lu ZP, Wu JL, Chen P, Jiang KR, Dai CC, Qian ZY, Xu ZK and Miao Y: Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep 23: 1375-1382, 2010.
33. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD and Bunn PA Jr.: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950, 2006. (Pubitemid 43165962)
34. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679, 2008.
35. Sarkar FH, Li Y, Wang Z and Kong D: Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 64: 489-500, 2009.
36. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.